- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03623425
Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer (TEPGALCHOL)
Comparison of PET Imaging With 68GA-PSMA-11 and 18F-Fluorocholine for the Identification of Site of Recurrence in Men With Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HBED-PSMA Sterile Cold Kit is a kit for preparation of radiolabelled 68Ga-PSMA-11. After radiolabelling with a 68Ga chloride solution complying with the requirements of monograph 2464 of the European Pharmacopoeia (Ph Eur), the solution may be used in men with biochemical relapse of prostate cancer after treatment. A large number of studies have been published on 68Ga-PSMA-ligands but none has yet been conducted with a product manufactured in accordance with ANMI technology. The aim of the study is to demonstrate the superiority of 68Ga-PSMA-11, prepared from a room temperature radiolabel kit containing PSMA-11 (PSMA-11 Sterile Cold Kit) and gallium 68 obtained from a 68Ge / 68Ga generator on 18F-Fluorocholine (18F-FCH) in identifying prostate cancer recurrence after radical treatment sites. So, patients will be evaluated with the current workup at CHRU of Nancy and will then be submitted to 68GA-PSMA-11 and 18F-FCH imaging. Patients will be randomized to the imaging procedure after workup in a 1/1 ratio between 68GA-PSMA-11 and comparator. So all patients will be submitted to 68GA-PSMA-11 and 18F-FCH; 50% of patients will receive the 68GA-PSMA-11 first; 50% of patients will receive the comparator first. There will be a time interval of minimum 7 days and maximum 14 days between both imaging procedures.
In order to mimic, as far as possible, the routine clinical practices, a sequential unblinding will be used for image readers. Readers will evaluate 68GA-PSMA-11 and 18F-FCH images with progressive access to more clinical information on each read. It will be done in three steps: fully blinded image evaluation, then image evaluation with results of the patient's clinical history and finally image evaluation with results of the patient's workup and clinical history.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Pierre OLIVIER, MD, PhD
- Phone Number: + 33 3 83 15 39 11
- Email: p.olivier@chru-nancy.fr
Study Contact Backup
- Name: Véronique ROCH, MSc
- Phone Number: +33 3 83 15 42 76
- Email: v.roch@chru-nancy.fr
Study Locations
-
-
-
Vandoeuvre Les Nancy, France, 54511
- CHRU de NANCY- BRABOIS
-
Contact:
- Pierre OLIVIER, MD, PhD
- Phone Number: + 33 3 83 15 39 11
- Email: p.olivier@chru-nancy.fr
-
Contact:
- Véronique ROCH, MSc
- Phone Number: +33 3 83 15 42 76
- Email: v.roch@chru-nancy.fr
-
Principal Investigator:
- Pierre OLIVIER, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult men ranging in age from 18 to 80
- Patient who have developed prostate cancer, and underwent radical treatment by prostatectomy or radiotherapy.
- PSA<10 ng/ml at inclusion
Rising prostate-specific antigen (PSA) after curative treatment of prostate cancer (radical prostatectomy or radiation therapy). Following definitions will apply:
Biochemical recurrence =
- After surgery: two sequential PSA values >0.2 ng/ml
- After radiation therapy: PSA increased by 2 ng/ml above nadir value
Residual disease =
- After surgery: positive PSA immediately after surgery or positive surgical margin
- After radiation therapy: two sequential PSA >0.2 ng/ml (to avoid false positive)
Progressive disease =
- PSA doubling time ≤ 6 months irrespective of initial PSA value
- Patients with a positron emission tomography with 18F-Fluorocholine (PET 18F-Fcholine) requested, as part of routine care.
- Estimated life-expectancy > 6 months
- Patients able to come for PET exams
- Patients affiliated to or beneficiary of a social security plan
- Patients physically and psychologically able to participate to the study
- Person informed about study organization and having signed the informed consent
- Patients who understood the principle and modalities of the study
- Person undergone the medical examination adapted to research
Exclusion Criteria:
- Known hypersensitivity to the active substance or to any excipient of the IMP
- Patients with known allergy to furosemide or sulfonamides. Other contraindications to furosemide do not apply to patients for whom the product will be used as a single dose
- Patients with a history of malignant pathology (except for basal-cell cutaneous carcinoma)
- Drug or alcohol dependence, serious current illness, mental disorder or any circumstance which, in the opinion of the investigator, could interfere with the conduct or interpretation of the study
- Exposure to another IMP within 60 days prior to inclusion
Person referred in articles L.1121-7 and L.1121-8 of the Public Health Code:
- Minor person (non-emancipated)
- Adult person under legal protection (any form of public guardianship)
- Adult person incapable of giving consent
- Person deprived of liberty for judicial or administrative decision, Person under psychiatric care according to articles L. 3212-1 and L. 3213-1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 68Ga-PSMA-11 PET before 18F-FCH PET
Crossover design
|
a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
|
Experimental: 18F-FCH PET before 68Ga-PSMA-11 PET
Crossover design
|
a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of lesions characteristic for prostate cancer detected by each TEP imaging method, by 68Ga-PSMA-11 and 18F-Fluorocholine
Time Frame: three months after the last PET exam for each patient
|
An experts committee will conduct a confirmatory assessment of all lesions three months after the last PET scan for each patient..
|
three months after the last PET exam for each patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count and characterize prostate cancer lesions for each method
Time Frame: three months after the last PET exam for each patient
|
Detection rate and Standardized Uptake Value (SUV) and tumor to background ratio (TBR)
|
three months after the last PET exam for each patient
|
Number of patients whose diagnosis and/or treatment are impacted by the results of the imaging procedures
Time Frame: three months after the last PET exam for each patient
|
Compare diagnoses and treatments decided with and without PET results
|
three months after the last PET exam for each patient
|
Sensitivity, specificity and predictive values of each tomography method
Time Frame: three months after the last PET exam for each patient
|
+ 95% CI
|
three months after the last PET exam for each patient
|
Number of adverse events and serious adverse events, whether or not related to research
Time Frame: three months after the last PET exam for each patient
|
Description of adverse events, incidence, severity, outcome and causality
|
three months after the last PET exam for each patient
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pierre OLIVIER, MD, PhD, CHRU de NANCY- BRABOIS
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-003620-69
- PSS2017/ANMI-OLIVIER/VS (Other Identifier: sponsor code)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on 68Ga-PSMA-11 PET
-
Irene BurgerCompletedProstate CancerSwitzerland
-
Thomas HopeGateway for Cancer Research; Prostate Cancer Foundation; Conquer Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
Sir Mortimer B. Davis - Jewish General HospitalCompleted
-
University Hospital, GhentCompleted
-
Xiangya Hospital of Central South UniversityRecruitingProstate CancerChina
-
Jules Bordet InstituteWithdrawn
-
Anhui Provincial HospitalRecruitingProstate Cancer | PET/CTChina
-
Peking Union Medical College HospitalRecruiting
-
Indiana UniversityCompleted
-
University Hospital, BordeauxRecruiting